Effect of intracerebroventricular injection of vasoactive intestinal polypeptide on systemic blood pressure and pancreatic and gastric secretions in the rat.

Mizuta K, Moriga M, Narusawa H, Uchino H, Aono M

Gastroenterologia Japonica1 Feb 1986Cited by 1 (Europe PMC)

PMID3699399DOI10.1007/bf02775941PepBankPUB-03699399

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In urethane-anesthetized rats, intravenous VIP had a systemic hypotensive effect.
In plain wordsIn rats, VIP given into a vein lowered blood pressure.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseSystemic blood pressure after intravenous VIP
Study
ratn: not reported in source
urethane-anesthetized rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
VIP, when given i.v., showed a systemic, hypotensive effect and a stimulatory effect on pancreatic secretion in urethane-anesthetized rats.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to examine the role of vasoactive intestinal polypeptide (VIP) in systemic blood pressure and pancreatic and gastric secretions in rats, the peptide was given to rats either intravenously (i.v.) through the femoral vein or intracerebroventricularly (i.c.v.) through the lateral ventricle.
Report a problemFND-0369939901
02AnimalAnimal study (in vivo)Efficacy outcome
In urethane-anesthetized rats, intravenous VIP stimulated pancreatic secretion.
In plain wordsIn rats, VIP given into a vein increased pancreatic secretion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePancreatic secretion after intravenous VIP
Study
ratn: not reported in source
urethane-anesthetized rats
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
VIP, when given i.v., showed a systemic, hypotensive effect and a stimulatory effect on pancreatic secretion in urethane-anesthetized rats.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to examine the role of vasoactive intestinal polypeptide (VIP) in systemic blood pressure and pancreatic and gastric secretions in rats, the peptide was given to rats either intravenously (i.v.) through the femoral vein or intracerebroventricularly (i.c.v.) through the lateral ventricle.
Report a problemFND-0369939902
03AnimalAnimal study (in vivo)Efficacy outcome
In urethane-anesthetized rats, intracerebroventricular VIP did not change systemic blood pressure.
In plain wordsIn rats, VIP given into the brain ventricle did not change blood pressure.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeSystemic blood pressure after intracerebroventricular VIP
Study
ratn: not reported in source
urethane-anesthetized rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
When VIP was given i.c.v., there was no change in systemic blood pressure and pancreatic secretion in urethane-anesthetized rats, nor in gastric secretion both in urethane-anesthetized, stomach-perfused rats and in conscious, chronic gastric fistula rats.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to examine the role of vasoactive intestinal polypeptide (VIP) in systemic blood pressure and pancreatic and gastric secretions in rats, the peptide was given to rats either intravenously (i.v.) through the femoral vein or intracerebroventricularly (i.c.v.) through the lateral ventricle.
Report a problemFND-0369939903
04AnimalAnimal study (in vivo)Efficacy outcome
In urethane-anesthetized rats, intracerebroventricular VIP did not change pancreatic secretion.
In plain wordsIn rats, VIP given into the brain ventricle did not change pancreatic secretion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePancreatic secretion after intracerebroventricular VIP
Study
ratn: not reported in source
urethane-anesthetized rats
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
When VIP was given i.c.v., there was no change in systemic blood pressure and pancreatic secretion in urethane-anesthetized rats, nor in gastric secretion both in urethane-anesthetized, stomach-perfused rats and in conscious, chronic gastric fistula rats.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to examine the role of vasoactive intestinal polypeptide (VIP) in systemic blood pressure and pancreatic and gastric secretions in rats, the peptide was given to rats either intravenously (i.v.) through the femoral vein or intracerebroventricularly (i.c.v.) through the lateral ventricle.
Report a problemFND-0369939904
05AnimalAnimal study (in vivo)Efficacy outcome
In urethane-anesthetized stomach-perfused rats and in conscious rats with a chronic gastric fistula, intracerebroventricular VIP did not change gastric secretion.
In plain wordsIn rats, VIP given into the brain ventricle did not change stomach secretion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeGastric secretion after intracerebroventricular VIP
Study
ratn: not reported in source
urethane-anesthetized rats
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
When VIP was given i.c.v., there was no change in systemic blood pressure and pancreatic secretion in urethane-anesthetized rats, nor in gastric secretion both in urethane-anesthetized, stomach-perfused rats and in conscious, chronic gastric fistula rats.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to examine the role of vasoactive intestinal polypeptide (VIP) in systemic blood pressure and pancreatic and gastric secretions in rats, the peptide was given to rats either intravenously (i.v.) through the femoral vein or intracerebroventricularly (i.c.v.) through the lateral ventricle.
Report a problemFND-0369939905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.